PURPOSE: Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable remission rates of approximately 40% in a clinical trial population. Whether this efficacy, and the rates of toxicity, would be consistent in a postcommercial setting, with relaxed eligibility criteria and bridging therapy, is unknown. This study describes the efficacy and safety correlates and outcomes in this setting. PATIENTS AND METHODS: One hundred twenty-two patients from 7 medical centers in the United States were treated with axi-cel and were included in a modified intent-to-treat (mITT) analysis. Seventy-six patients (62%) were ineligible for the ZUMA-1 trial. Response and toxicity rates, duration of response (DOR), survival, and covariates are described on the basis of the mITT population. Correlative studies on blood and tumor samples were performed to investigate potential biomarkers of response and resistance. RESULTS: Median follow-up was 10.4 months. In the mITT population, the best overall and complete response (CR) rates were 70% and 50%, respectively. Median DOR and progression-free survival (PFS) were 11.0 and 4.5 months in all patients and were not reached (NR) in CR patients. Median overall survival (OS) was NR; 1-year OS was 67% (95% CI, 59% to 77%). Although response rates were similar in the ZUMA-1-eligible and ZUMA-1-ineligible groups (70% v 68%), there was a statistically significant improvement in CR rate (63% v 42%, P = .016), DOR (median, NR v 5.0 months; P = .014), PFS (median, NR v 3.3 months; P = .020), and OS (1-year OS, 89% v 54%; P < .001) in patients who were ZUMA-1 eligible. Rates of grade ≥ 3 cytokine release syndrome and neurotoxicty were 16% and 35%, respectively. CONCLUSION: Axi-cel yields similar rates of overall response and toxicity in commercial and trial settings, although CR rates and DOR were more favorable in patients eligible for ZUMA-1.
PURPOSE: Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable remission rates of approximately 40% in a clinical trial population. Whether this efficacy, and the rates of toxicity, would be consistent in a postcommercial setting, with relaxed eligibility criteria and bridging therapy, is unknown. This study describes the efficacy and safety correlates and outcomes in this setting. PATIENTS AND METHODS: One hundred twenty-two patients from 7 medical centers in the United States were treated with axi-cel and were included in a modified intent-to-treat (mITT) analysis. Seventy-six patients (62%) were ineligible for the ZUMA-1 trial. Response and toxicity rates, duration of response (DOR), survival, and covariates are described on the basis of the mITT population. Correlative studies on blood and tumor samples were performed to investigate potential biomarkers of response and resistance. RESULTS: Median follow-up was 10.4 months. In the mITT population, the best overall and complete response (CR) rates were 70% and 50%, respectively. Median DOR and progression-free survival (PFS) were 11.0 and 4.5 months in all patients and were not reached (NR) in CR patients. Median overall survival (OS) was NR; 1-year OS was 67% (95% CI, 59% to 77%). Although response rates were similar in the ZUMA-1-eligible and ZUMA-1-ineligible groups (70% v 68%), there was a statistically significant improvement in CR rate (63% v 42%, P = .016), DOR (median, NR v 5.0 months; P = .014), PFS (median, NR v 3.3 months; P = .020), and OS (1-year OS, 89% v 54%; P < .001) in patients who were ZUMA-1 eligible. Rates of grade ≥ 3 cytokine release syndrome and neurotoxicty were 16% and 35%, respectively. CONCLUSION: Axi-cel yields similar rates of overall response and toxicity in commercial and trial settings, although CR rates and DOR were more favorable in patients eligible for ZUMA-1.
Authors: Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht Journal: Blood Date: 2017-08-03 Impact factor: 22.113
Authors: E Van Den Neste; N Schmitz; N Mounier; D Gill; D Linch; M Trneny; N Milpied; J Radford; N Ketterer; O Shpilberg; U Dührsen; D Ma; J Brière; C Thieblemont; G Salles; C H Moskowitz; B Glass; C Gisselbrecht Journal: Bone Marrow Transplant Date: 2015-09-14 Impact factor: 5.483
Authors: Felicitas Hitz; J M Connors; R D Gascoyne; P Hoskins; A Moccia; K J Savage; L H Sehn; T Shenkier; D Villa; R Klasa Journal: Ann Hematol Date: 2015-08-07 Impact factor: 3.673
Authors: Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245
Authors: Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney Journal: J Clin Oncol Date: 2017-07-17 Impact factor: 44.544
Authors: Jeremy S Abramson; Brianne McGree; Sarah Noyes; Sean Plummer; Curtis Wong; Yi-Bin Chen; Edwin Palmer; Tina Albertson; Judith A Ferry; Isabel C Arrillaga-Romany Journal: N Engl J Med Date: 2017-08-24 Impact factor: 91.245
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli Journal: J Clin Invest Date: 2016-07-25 Impact factor: 14.808
Authors: Sarah J Nagle; Kaitlin Woo; Stephen J Schuster; Sunita D Nasta; Edward Stadtmauer; Rosemarie Mick; Jakub Svoboda Journal: Am J Hematol Date: 2013-08-01 Impact factor: 10.047
Authors: Peter Dreger; Sascha Dietrich; Maria-Luisa Schubert; Lorenz Selberg; Andrea Bondong; Mandy Wegner; Peter Stadtherr; Christoph Kimmich; Florentina Kosely; Anita Schmitt; Petra Pavel; Nora Liebers; Thomas Luft; Ute Hegenbart; Aleksandar Radujkovic; Anthony Dick Ho; Carsten Müller-Tidow; Michael Schmitt Journal: Blood Adv Date: 2020-12-22
Authors: Marta Garcia-Recio; Kitsada Wudhikarn; Martina Pennisi; Rosalia Alonso-Trillo; Jessica Flynn; Roni Shouval; Aishat O Afuye; Mari Lynne Silverberg; Connie W Batlevi; Parastoo Dahi; Sean Devlin; Sergio A Giralt; Elizabeth Halton; Josel Ruiz; Molly Maloy; Elena Mead; M Lia Palomba; Bianca Santomasso; Craig S Sauter; Michael Scordo; Gunjan L Shah; Miguel-Angel Perales Journal: Transplant Cell Ther Date: 2020-12-18
Authors: Mazyar Shadman; Marcelo Pasquini; Kwang Woo Ahn; Yue Chen; Cameron J Turtle; Peiman Hematti; Jonathon B Cohen; Farhad Khimani; Siddhartha Ganguly; Reid W Merryman; Jean A Yared; Frederick L Locke; Nausheen Ahmed; Pashna N Munshi; Amer Beitinjaneh; Patrick M Reagan; Alex F Herrera; Craig S Sauter; Mohamed A Kharfan-Dabaja; Mehdi Hamadani Journal: Blood Date: 2022-03-03 Impact factor: 22.113
Authors: Jennifer L Crombie; Loretta J Nastoupil; Robert Redd; Kevin Tang; Geoffrey Shouse; Alex F Herrera; Victor A Chow; Mazyar Shadman; Omar Castaneda Puglianini; Anna Saucier; Caron A Jacobson; Philippe Armand; Gary Simmons Journal: Blood Adv Date: 2021-09-28
Authors: Kai Rejeski; Ariel Perez; Pierre Sesques; Eva Hoster; Carolina Berger; Liv Jentzsch; Dimitrios Mougiakakos; Lisa Frölich; Josephine Ackermann; Veit Bücklein; Viktoria Blumenberg; Christian Schmidt; Laurent Jallades; Boris Fehse; Christoph Faul; Philipp Karschnia; Oliver Weigert; Martin Dreyling; Frederick L Locke; Michael von Bergwelt-Baildon; Andreas Mackensen; Wolfgang Bethge; Francis Ayuk; Emmanuel Bachy; Gilles Salles; Michael D Jain; Marion Subklewe Journal: Blood Date: 2021-12-16 Impact factor: 22.113